Inozyme Pharma, Inc. Board of Directors
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Dr. Demetrios Braddock M.D., Ph.D.
Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer
Mr. Sanjay S. Subramanian M.B.A., M.S.
Senior VP, CFO, Principal Accounting Officer & Corporate Secretary
Leaving Board of Directors Review
Your about to visit the following url
Invalid URL
Loading...
Comments
Comment created.